Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutid...
3 transactions — including 0 buys declared by Vivani Medical, Inc. executives to SEC / AMF / BaFin.
8 institutional funds report a position on VANI in their latest SEC quarterly filing.
15 recent articles on VANI.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Automatic detection when 3+ executives buy the same stock simultaneously — historically the most reliable signal.
Berkshire (Buffett), Pershing Square (Ackman), Tiger Global, Bridgewater + 200 more. Who buys what, each quarter.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot small caps whose retail interest explodes before the rest of the market. 100+ tickers monitored.
Create your watchlist and receive every morning at 8am the Brief of events on YOUR tickers.
This public page only shows a preview. The full analysis of VANI on the Kairos Insider dashboard includes:
Free signup · Premium €29/month no commitment